Search the Newsreel

Anheuser-Busch InBev SA/NV (BUD) Earnings Date and Reports 2026 $BUD

Bausch + Lomb (NYSE: BLCO) lifts revenue but remains loss-making

Is Bausch + Lomb (BLCO) Undervalued As EyeGility Launch And Earnings Draw Focus?

Bausch + Lomb Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:BLCO) 2026-07-29

Bausch + Lomb (BLCO) reported strong Q2 2026 results, with an 8% constant currency revenue growth and a 28% increase in adjusted EBITDA, leading to a 17.6% adjusted EBITDA margin. The company raised its full-year revenue and adjusted EBITDA guidance, driven by consistent performance …

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 9.1% year on year to $1.39 billion. The company expects the full year's revenue to be around …

Bausch Health Rises After Q2 Earnings, Revenue Beat Estimates

Bausch + Lomb: Q2 Earnings Snapshot

Bausch + Lomb Corporation reported a Q2 loss of $14 million, or 4 cents per share, which adjusted to 16 cents per share, meeting Wall Street expectations. The company recorded revenue of $1.39 billion, exceeding analyst forecasts, and anticipates full-year revenue between $5.42 billion …

Bausch Health Companies Inc (BHC) Valuation: PE, PB & Fair Value Analysis

Bausch Health Companies Inc (BHC) has a current valuation score of 9.34, ranking 27th out of 155 companies in the Pharmaceuticals industry. The company's P/E ratio is -1.40, which is significantly below its recent high and above its recent low. However, relevant data for …

Bausch + Lomb Corp (BLCO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Bausch + Lomb Corp (BLCO), rating its current risk score at 7.06, placing it 43rd out of 199 in the Healthcare Equipment & Supplies industry. Key metrics include a beta of 0.58, indicating lower volatility compared to …

Bausch Health Companies Inc (BHC) Risk Assessment: Volatility, Financial Risk & Investment Risk

Bausch Health Companies Inc (BHC) has a current risk assessment score of 6.07, ranking 59 out of 155 in the Pharmaceuticals industry. The company's beta value of 0.42 indicates it may underperform during bull markets but experience smaller declines during bear markets. The report …

Stocks in play: Bausch Health Companies Inc.

Bausch Health Companies Inc. (T.BHC) announced that its PrELIDEL (pimecrolimus) cream is now approved for listing under Alberta's public drug plan for eligible patients. Following this announcement, the company's shares are trading up by $0.09 at $6.43.

Bausch Health Companies Inc.

Bausch Health Companies Inc. announced that its PrELIDEL® (pimecrolimus) cream has been listed under Alberta's public drug plan, making it available for eligible patients. Following this announcement, shares of Bausch Health Companies Inc. (T.BHC) saw an increase, trading up $0.09 at $6.43.

1 Reason to Buy NuScale Power Stock This August

NuScale Power (NYSE: SMR) remains one of the most popular nuclear energy stocks on the planet. And it's not hard to understand why. Bank of America analysts believe we're entering a nuclear renaissance driven by rising energy demand stemming from the global adoption of …

(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis

LAVAL, QC, July 28, 2026 /PRNewswire/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) announces that PrELIDEL® (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible patients. ELIDEL® cream is indicated for second-line therapy …

What Could Drive the Next Phase of Nuclear Energy Growth?

Nuclear energy is moving back into the center of the global power debate. Electricity demand is rising as data centers, manufacturing plants and transportation systems consume more power, while governments and large companies are also seeking dependable, lower-carbon energy. Unlike weather-dependent resources, nuclear plants …

Maverick Capital Ltd. Grows Stake in Anheuser-Busch InBev SA/NV $BUD

Maverick Capital Ltd. increased its holdings in Anheuser-Busch InBev SA/NV (NYSE:BUD) by 42.1% in the first quarter, now owning 51,020 shares valued at $3.54 million. Other institutional investors also boosted their stakes, reflecting a positive sentiment towards the company. Wall Street analysts maintain a …

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

Bausch + Lomb (BLCO) is set to report earnings tomorrow, with expectations for revenue growth of 7.2% year-on-year. The company has a strong record of beating revenue estimates, and analysts have reconfirmed their projections. Investors will be watching how BLCO performs compared to peers …

Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System

Bausch + Lomb has launched its new EyeGility Inserter preloaded IOL delivery system in the U.S. This system is designed for use with enVista Aspire and Envy IOLs, offering convenient one-handed operation and smooth delivery with a silicon soft-tipped plunger. The EyeGility Inserter aims …

TruScreen Group Ltd. Revenue Breakdown – NZX:TRU

Bausch + Lomb Corporation Revenue Breakdown – MUN:S2L

Bausch + Lomb Corporation (MUN:S2L) generated €4.34 billion in revenue last year, with its Vision Care segment contributing the most at €2.49 billion. Geographically, the United States and Puerto Rico was the largest source of revenue, accounting for €2.17 billion. This data provides a …

Investor Outlook: Bausch + Lomb Corporation (BLCO) Eyes 12% Upside Potential Amid Steady Growth

Bausch + Lomb Corporation (BLCO), a healthcare company specializing in medical instruments, shows a stable performance with an intriguing opportunity for investors. Despite negative EPS and ROC, the company demonstrates strong revenue growth and free cash flow, indicative of strategic reinvestment for long-term growth. …

Bausch Health Companies Inc expected to post earnings of $1.01 a share - Earnings Preview

Bausch Health Companies Inc. is projected to report earnings of $1.01 per share. This information comes from an earnings preview provided by Refinitiv. The article provides a headline and directs readers to TradingView for the full article.

Anheuser-Busch InBev stock steadies as cost controls support margins and cash flow

Anheuser-Busch InBev's stock performance is stabilized by disciplined cost control, improving margins, and strong cash generation, despite an elevated debt load. In fiscal 2023, the company reported robust financials including $59.4 billion in revenue, $19.7 billion in EBITDA, and $8.9 billion in free cash …

Bold Prediction: NuScale Power Is About to Break Out

Key Points NuScale's stock has dropped over 80% in the past 12 months. The company's largest shareholder, Fluor, fully exited the company this year. NuScale's SMR design was the first to receive approval from the Nuclear Regulatory Commission.10 stocks we like better than NuScale …

What Analyst Projections for Key Metrics Reveal About Anheuser-Busch Inbev (BUD) Q2 Earnings

The upcoming report from Anheuser-Busch Inbev (BUD) is expected to reveal quarterly earnings of $1.09 per share, indicating an increase of 11.2% compared to the year-ago period. Analysts forecast revenues of $16.29 billion, representing an increase of 8.6% year over year. Over the last …

Anheuser-Busch InBev SA/NV's (BUD) "Equal Weight" Rating Reaffirmed at Barclays

Barclays has reaffirmed its "Equal Weight" rating for Anheuser-Busch InBev SA/NV (BUD), while the broader analyst consensus remains a "Moderate Buy" with an average price target of $90.08. The company's stock opened at $81.67, with a market capitalization of $159.3 billion, and has seen …

Renaissance Technologies LLC Acquires 318,600 Shares of Anheuser-Busch InBev SA/NV $BUD

Renaissance Technologies LLC significantly increased its stake in Anheuser-Busch InBev SA/NV (NYSE:BUD) during the first quarter, purchasing an additional 318,600 shares, bringing its total holdings to 810,874 shares valued at $56.25 million. Analysts maintain a "Moderate Buy" rating for BUD with an average price …

Bausch + Lomb Corp (BLCO) Cash Flow

This article provides an in-depth look at Bausch + Lomb Corp's (BLCO) cash flow statements, including operating, investing, and financing activities, presented quarterly and annually. It details changes in various cash flow components over several fiscal quarters and years, offering insights into the company's …

US1 Critical Minerals Limited Proposes Issue of 25 Million Options to Support Business Development

Anheuser-Busch InBev stock trades steady as recent earnings highlight debt reduction and cash flow s

Anheuser-Busch InBev's recent earnings show stable trading driven by a strong focus on debt reduction, consistent free cash flow generation, and disciplined capital allocation. The company achieved mid-single-digit revenue growth through pricing and brand mix improvements, alongside incremental EBITDA growth, contributing to a gradual …

Anheuser-Busch InBev stock steadies as cost control supports earnings momentum

Anheuser-Busch InBev (AB InBev) has demonstrated earnings momentum through disciplined cost control and ongoing debt reduction, despite only modest volume growth. The company reported increased revenue and normalized EBITDA in fiscal 2025, driven by pricing and efficiency measures rather than sheer volume expansion. AB …

Prediction: Buying NuScale Power Today Could Set You Up for Life

Key Points The recent slide in NuScale Power stock could be setting it up for a big, long-term gain. The company has two projects underway, but neither will likely materialize within the next five years. NuScale investors should be ready for near-term volatility and …

Healthcare of Ontario Pension Plan Trust Fund Sells 452,119 Shares of Bausch Health Cos Inc. $BHC

The Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Bausch Health Cos Inc. by 5.3% in Q1 2026, selling 452,119 shares and retaining 8 million shares valued at $43.2 million. Other institutional investors adjusted their holdings, and director Frank D. Lee …

BHC|Bausch Health Companies Inc|Price:4.430|Chg%:-0.015

This article provides a detailed financial overview of Bausch Health Companies Inc (BHC), including its stock price, market capitalization, and key financial indicators. It presents extensive quarterly and annual data for income statements, balance sheets, and cash flow statements, along with analyst ratings. The …

Bausch + Lomb Corp (BLCO) Institutional Confidence

Bausch + Lomb Corp (BLCO) has an institutional shareholding score of 3.00, ranking 131 out of 200 in its industry, with the institutional shareholding proportion decreasing by 34.15% quarter-over-quarter to 11.30%. Carl Icahn is the largest institutional shareholder, holding 3.54 million shares, representing 0.98% …

Anheuser-Busch InBev stock steadies as investors weigh earnings recovery and debt reduction

Anheuser-Busch InBev's stock is stabilizing as investors consider its gradual earnings recovery and ongoing debt reduction. The company, facing challenges from pandemic demand swings and US brand issues, is focusing on cash flow, margin improvement, and deleveraging, with mid-single-digit revenue growth and a declining …